GRIFOLS S A/S (GRFS) Holdings Increased by Regentatlantic Capital LLC

Regentatlantic Capital LLC raised its position in GRIFOLS S A/S (NASDAQ:GRFS) by 43.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 66,646 shares of the biotechnology company’s stock after acquiring an additional 20,324 shares during the quarter. Regentatlantic Capital LLC’s holdings in GRIFOLS S A/S were worth $1,424,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the business. First Trust Advisors LP lifted its stake in GRIFOLS S A/S by 85.7% in the third quarter. First Trust Advisors LP now owns 4,634,749 shares of the biotechnology company’s stock valued at $99,045,000 after acquiring an additional 2,139,441 shares during the last quarter. Vaughan Nelson Investment Management L.P. lifted its stake in GRIFOLS S A/S by 5.1% in the second quarter. Vaughan Nelson Investment Management L.P. now owns 3,021,901 shares of the biotechnology company’s stock valued at $64,971,000 after acquiring an additional 147,715 shares during the last quarter. SG Americas Securities LLC lifted its stake in GRIFOLS S A/S by 38,886.6% in the second quarter. SG Americas Securities LLC now owns 3,001,189 shares of the biotechnology company’s stock valued at $64,526,000 after acquiring an additional 2,993,491 shares during the last quarter. Engadine Partners LLP lifted its stake in GRIFOLS S A/S by 18.0% in the second quarter. Engadine Partners LLP now owns 2,906,319 shares of the biotechnology company’s stock valued at $62,486,000 after acquiring an additional 443,386 shares during the last quarter. Finally, Gladstone Capital Management LLP lifted its stake in GRIFOLS S A/S by 22.1% in the second quarter. Gladstone Capital Management LLP now owns 1,375,539 shares of the biotechnology company’s stock valued at $29,299,000 after acquiring an additional 248,850 shares during the last quarter. Hedge funds and other institutional investors own 21.07% of the company’s stock.

NASDAQ GRFS opened at $20.80 on Friday. The company has a quick ratio of 1.12, a current ratio of 2.90 and a debt-to-equity ratio of 1.52. The stock has a market cap of $14.18 billion, a PE ratio of 18.91, a P/E/G ratio of 1.45 and a beta of 1.21. GRIFOLS S A/S has a 52-week low of $17.47 and a 52-week high of $25.18.

A number of analysts have commented on the stock. Zacks Investment Research upgraded shares of GRIFOLS S A/S from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 1st. BidaskClub cut shares of GRIFOLS S A/S from a “sell” rating to a “strong sell” rating in a research note on Friday, July 13th. UBS Group cut shares of GRIFOLS S A/S from a “neutral” rating to a “sell” rating in a research note on Wednesday, October 3rd. Santander upgraded shares of GRIFOLS S A/S from an “underperform” rating to a “hold” rating in a research note on Tuesday. Finally, Berenberg Bank upgraded shares of GRIFOLS S A/S from a “hold” rating to a “buy” rating in a research note on Thursday, October 11th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and three have given a buy rating to the company. GRIFOLS S A/S has an average rating of “Hold” and an average price target of $21.50.

GRIFOLS S A/S Profile

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others.

Further Reading: Initial Public Offering (IPO)

Want to see what other hedge funds are holding GRFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GRIFOLS S A/S (NASDAQ:GRFS).

Institutional Ownership by Quarter for GRIFOLS S A/S (NASDAQ:GRFS)

Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply